Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Achaogen closes $26.5mm Series B round

19 Oct 2006

Executive Summary

Achaogen (developing small molecules for bacterial infections and antibiotic-resistant strains) brought in $26.5mm with its Series B financing led by first-time backer Domain Venture Partners. Returning shareholders 5AM Ventures, ARCH Venture Partners, Venrock Associates, and Versant Ventures also participated. The company will use the money to advance its three preclinical antibacterial programs--two broad-spectrum antibiotics and a compound for gram-positive and gram-negative pathogens. A member of Domain will take a seat on Achaogen's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By